VectivBio is a biotechnology company committed to making a difference in the lives of patients suffering from serious rare diseases.
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care.It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 30, 2022 | Post-IPO Debt | $75M | 1 | Kreos Capital | — | Detail |
Oct 19, 2020 | Series Unknown | $110M | 2 | — | — | Detail |
Jan 8, 2020 | Series A | $35M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Kreos Capital | Yes | Post-IPO Debt |
Inserm Transfert Initiative | — | Series Unknown |
Versant Ventures | — | Series Unknown |